Alchemia Names New CEOBy
The Australian pharmaceutical company Alchemia Limited has appointed Thomas Liquard as chief executive officer following the departure of Charles Walker. Liquard, who joined Alchemia in December 2013 as chief operating officer, brings commercial and managerial expertise to the company having most recently served as senior director, portfolio development lead emerging markets for the established products portfolio at Pfizer.
Alchemia is marketing FDA approved fondaparinux, an injectible antithrombotic in the US, as well as other major markets via partner Dr. Reddy's Laboratories. The company is also developing a late-stage oncology product pipeline with multiple ongoing trials through its proprietary HyACT drug delivery platform, which targets anti-cancer drugs to solid tumours. Its lead asset HA-Irinotecan is in Phase III development.